Merck Reports final analysis Data for Ubrogepant in Cystic fibrosis

Merck today announced final analysis results for Ubrogepant in patients with Cystic fibrosis. The study demonstrated that Ubrogepant improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Cystic fibrosis and support the continued development of Ubrogepant in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ubrogepant was consistent with previous observations, with no new safety signals identified.